SEHK:2171Biotechs
CARsgen Therapeutics Holdings (SEHK:2171) Stock Looks Rich Even After New CAR T Data
CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after presenting new clinical data for its allogeneic CAR T-cell candidates CT0596 and CT1190B at the 2026 European Hematology Association Congress.
See our latest analysis for CARsgen Therapeutics Holdings.
The latest clinical updates arrive after a mixed stretch for CARsgen Therapeutics Holdings shares, with the stock currently trading at HK$15.83. The 7 day share price return of 4.14% contrasts with a 30 day share price...